Vanguard Group
VYNE icon

Vanguard Group’s VYNE Therapeutics VYNE Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$819K Buy
496,297
+20,647
+4% +$34.1K ﹤0.01% 3795
2025
Q1
$752K Buy
475,650
+521
+0.1% +$823 ﹤0.01% 3789
2024
Q4
$1.59M Buy
475,129
+31,611
+7% +$106K ﹤0.01% 3632
2024
Q3
$834K Hold
443,518
﹤0.01% 3825
2024
Q2
$874K Buy
443,518
+373,885
+537% +$737K ﹤0.01% 3836
2024
Q1
$214K Buy
69,633
+20,051
+40% +$61.6K ﹤0.01% 4168
2023
Q4
$116K Buy
49,582
+4,687
+10% +$10.9K ﹤0.01% 4285
2023
Q3
$181K Sell
44,895
-1
-0% -$4 ﹤0.01% 4270
2023
Q2
$184K Buy
44,896
+7,038
+19% +$28.9K ﹤0.01% 4323
2023
Q1
$117K Sell
37,858
-1,612,749
-98% -$4.97M ﹤0.01% 4390
2022
Q4
$248K Buy
1,650,607
+1,118
+0.1% +$168 ﹤0.01% 4268
2022
Q3
$368K Sell
1,649,489
-151,041
-8% -$33.7K ﹤0.01% 4297
2022
Q2
$700K Buy
1,800,530
+320,604
+22% +$125K ﹤0.01% 4198
2022
Q1
$962K Sell
1,479,926
-766,305
-34% -$498K ﹤0.01% 4219
2021
Q4
$2.29M Sell
2,246,231
-190,201
-8% -$194K ﹤0.01% 3989
2021
Q3
$3.39M Hold
2,436,432
﹤0.01% 3867
2021
Q2
$8.55M Sell
2,436,432
-52,829
-2% -$185K ﹤0.01% 3291
2021
Q1
$17M Sell
2,489,261
-5,053,334
-67% -$34.6M ﹤0.01% 2864
2020
Q4
$11.9M Buy
7,542,595
+470,121
+7% +$743K ﹤0.01% 2903
2020
Q3
$11.7M Buy
7,072,474
+71,908
+1% +$119K ﹤0.01% 2708
2020
Q2
$12.1M Buy
7,000,566
+5,982,365
+588% +$10.3M ﹤0.01% 2669
2020
Q1
$2.73M Buy
1,018,201
+487,907
+92% +$1.31M ﹤0.01% 3214
2019
Q4
$2.46M Sell
530,294
-1,541
-0.3% -$7.15K ﹤0.01% 3389
2019
Q3
$2.38M Sell
531,835
-27,664
-5% -$124K ﹤0.01% 3392
2019
Q2
$3.35M Buy
559,499
+22,996
+4% +$138K ﹤0.01% 3306
2019
Q1
$4.21M Buy
536,503
+378,223
+239% +$2.97M ﹤0.01% 3197
2018
Q4
$653K Sell
158,280
-300,651
-66% -$1.24M ﹤0.01% 3675
2018
Q3
$4.52M Buy
458,931
+197,188
+75% +$1.94M ﹤0.01% 3275
2018
Q2
$2.13M Buy
261,743
+59,056
+29% +$479K ﹤0.01% 3479
2018
Q1
$7.62M Buy
+202,687
New +$7.62M ﹤0.01% 2959